ReviewThe journal of headache and pain2018
PACAP and migraine headache: immunomodulation of neural circuits in autonomic ganglia and brain parenchyma.
Review in The journal of headache and pain, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 66 citations in OpenAlex.
- Serum CGRP, VIP, and PACAP usefulness in migraine: a case-control study in chronic migraine patients in real clinical practice.Molecular biology reports · 2020Trial
- Tear Fluid Calcitonin Gene-Related Peptide Levels Are Elevated in Glycerol Trinitrate-Induced Cluster Headache Attacks: Results From an Exploratory Study.European journal of neurology · 2026Article
- New Directions in Migraine Pathophysiology: The Glymphatic System and PACAP.Life (Basel, Switzerland) · 2026Review
- PACAP versus CGRP in migraine: From mouse models to clinical translation.Cephalalgia : an international journal of headache · 2025Review
- Possible Role of Novel Mitochondrial Subsets in Migraine.Life (Basel, Switzerland) · 2025Review
- Influence of triptans use on anti-CGRP mAbs response: a prospective, cohort study.Journal of neurology · 2025Article
- Hallmarks of primary headache: part 1 - migraine.The journal of headache and pain · 2024Review
- Review
- The Brain, the Eating Plate, and the Gut Microbiome: Partners in Migraine Pathogenesis.Nutrients · 2024Review
- PAC1 receptor modulation of freezing and flight behavior in periaqueductal gray.Genes, brain, and behavior · 2023Article
- Exploring Facial Thermography Patterns in Women with Chronic Migraine.Journal of clinical medicine · 2023Article
- From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment.Cells · 2023Review
- Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review.Neurology and therapy · 2023Review
- Central generators of migraine and autonomic cephalalgias as targets for personalized pain management: Translational links.European journal of pain (London, England) · 2023Review
- Molecular and Cellular Neurobiology of Circadian and Circannual Rhythms in Migraine: A Narrative Review.International journal of molecular sciences · 2023Review
- Pharmacological evaluation of carvacrol anti-migraine potential.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience.The journal of headache and pain · 2023Article
- PACAP-PAC1 receptor inhibition is effective in opioid induced hyperalgesia and medication overuse headache models.iScience · 2023Article
- Exploration of phytochemicals and probing potential effects of3 Biotech · 2023Article
- Hypoxia-related mechanisms inducing acute mountain sickness and migraine.Frontiers in physiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery that intravenous (IV) infusions of the neuropeptide PACAP-38 (pituitary adenylyl cyclase activating peptide-38) induced delayed migraine-like headaches in a large majority of migraine patients has resulted in considerable excitement in headache research. In addition to suggesting potential therapeutic targets for migraine, the finding provides an opportunity to better understand the pathological events from early events (aura) to the headache itself. Although PACAP-38 and the closely related peptide VIP (vasoactive intestinal peptide) are well-known as vasoactive molecules, the dilation of cranial blood vessels per se is no longer felt to underlie migraine headaches. Thus, more recent research has focused on other possible PACAP-mediated mechanisms, and has raised some important questions. For example, (1) are endogenous sources of PACAP (or VIP) involved in the triggering and/or propagation of migraine headaches?; (2) which receptor subtypes are involved in migraine pathophysiology?; (3) can we identify specific anatomical circuit(s) where PACAP signaling is involved in the features of migraine? The purpose of this review is to discuss the possibility, and supportive evidence, that PACAP acts to induce migraine-like symptoms not only by directly modulating nociceptive neural circuits, but also by indirectly regulating the production of inflammatory mediators. We focus here primarily on postulated extra-dural sites because potential mechanisms of PACAP action in the dura are discussed in detail elsewhere (see X, this edition).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.